IL127342A - A method for detecting nucleic acid that includes methylated GPC, a kit for using the method and a method for detecting a disease related to the methylation of nucleic acid - Google Patents
A method for detecting nucleic acid that includes methylated GPC, a kit for using the method and a method for detecting a disease related to the methylation of nucleic acidInfo
- Publication number
- IL127342A IL127342A IL12734297A IL12734297A IL127342A IL 127342 A IL127342 A IL 127342A IL 12734297 A IL12734297 A IL 12734297A IL 12734297 A IL12734297 A IL 12734297A IL 127342 A IL127342 A IL 127342A
- Authority
- IL
- Israel
- Prior art keywords
- nucleic acid
- methylated
- primers
- dna
- cpg
- Prior art date
Links
- 238000007069 methylation reaction Methods 0.000 title claims abstract description 92
- 230000011987 methylation Effects 0.000 title claims abstract description 91
- 238000000034 method Methods 0.000 title claims abstract description 81
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 79
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 78
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 78
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 21
- 201000010099 disease Diseases 0.000 title description 4
- 238000001514 detection method Methods 0.000 claims abstract description 33
- 239000013615 primer Substances 0.000 claims description 154
- 108020004414 DNA Proteins 0.000 claims description 116
- 210000004027 cell Anatomy 0.000 claims description 83
- 108090000623 proteins and genes Proteins 0.000 claims description 58
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 claims description 51
- 238000003752 polymerase chain reaction Methods 0.000 claims description 50
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 claims description 49
- 230000003321 amplification Effects 0.000 claims description 44
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 44
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 32
- 239000000523 sample Substances 0.000 claims description 32
- 210000001519 tissue Anatomy 0.000 claims description 32
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical group OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 31
- 108091029523 CpG island Proteins 0.000 claims description 24
- 239000003153 chemical reaction reagent Substances 0.000 claims description 21
- 108091008146 restriction endonucleases Proteins 0.000 claims description 21
- -1 TGF-betal Proteins 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 102000004190 Enzymes Human genes 0.000 claims description 17
- 108090000790 Enzymes Proteins 0.000 claims description 17
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 17
- 208000035475 disorder Diseases 0.000 claims description 17
- 230000006607 hypermethylation Effects 0.000 claims description 15
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims description 14
- 102000040430 polynucleotide Human genes 0.000 claims description 13
- 108091033319 polynucleotide Proteins 0.000 claims description 13
- 239000002157 polynucleotide Substances 0.000 claims description 13
- 230000002062 proliferating effect Effects 0.000 claims description 13
- 108700025716 Tumor Suppressor Genes Proteins 0.000 claims description 12
- 102000044209 Tumor Suppressor Genes Human genes 0.000 claims description 12
- 208000029742 colonic neoplasm Diseases 0.000 claims description 11
- 101001134036 Homo sapiens DNA mismatch repair protein Msh2 Proteins 0.000 claims description 10
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 10
- 201000005202 lung cancer Diseases 0.000 claims description 10
- 208000020816 lung neoplasm Diseases 0.000 claims description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 9
- 102100034157 DNA mismatch repair protein Msh2 Human genes 0.000 claims description 9
- 239000003155 DNA primer Substances 0.000 claims description 8
- 239000000872 buffer Substances 0.000 claims description 8
- 108010038795 estrogen receptors Proteins 0.000 claims description 8
- 229940035893 uracil Drugs 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 102100037738 Fatty acid-binding protein, heart Human genes 0.000 claims description 7
- 101710136552 Fatty acid-binding protein, heart Proteins 0.000 claims description 7
- 206010036790 Productive cough Diseases 0.000 claims description 7
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 7
- 210000001072 colon Anatomy 0.000 claims description 7
- 102000015694 estrogen receptors Human genes 0.000 claims description 7
- 210000003802 sputum Anatomy 0.000 claims description 7
- 208000024794 sputum Diseases 0.000 claims description 7
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 claims description 6
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 claims description 6
- 229910015837 MSH2 Inorganic materials 0.000 claims description 6
- 108091034117 Oligonucleotide Proteins 0.000 claims description 6
- 229940104302 cytosine Drugs 0.000 claims description 6
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 claims description 6
- 102000052609 BRCA2 Human genes 0.000 claims description 5
- 108700020462 BRCA2 Proteins 0.000 claims description 5
- 101150008921 Brca2 gene Proteins 0.000 claims description 5
- 102000055006 Calcitonin Human genes 0.000 claims description 5
- 108060001064 Calcitonin Proteins 0.000 claims description 5
- 102100031612 Hypermethylated in cancer 1 protein Human genes 0.000 claims description 5
- 101710133850 Hypermethylated in cancer 1 protein Proteins 0.000 claims description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 5
- 108010026664 MutL Protein Homolog 1 Proteins 0.000 claims description 5
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 5
- 239000013060 biological fluid Substances 0.000 claims description 5
- 210000000481 breast Anatomy 0.000 claims description 5
- 229960004015 calcitonin Drugs 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 210000004072 lung Anatomy 0.000 claims description 5
- 239000002853 nucleic acid probe Substances 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 102100032187 Androgen receptor Human genes 0.000 claims description 4
- 102000013128 Endothelin B Receptor Human genes 0.000 claims description 4
- 108010090557 Endothelin B Receptor Proteins 0.000 claims description 4
- 101000613251 Homo sapiens Tumor susceptibility gene 101 protein Proteins 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 102100040879 Tumor susceptibility gene 101 protein Human genes 0.000 claims description 4
- 108010080146 androgen receptors Proteins 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 4
- 210000003296 saliva Anatomy 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 102000007530 Neurofibromin 1 Human genes 0.000 claims description 3
- 108010085793 Neurofibromin 1 Proteins 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 239000007850 fluorescent dye Substances 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 101000954986 Homo sapiens Merlin Proteins 0.000 claims description 2
- 208000000172 Medulloblastoma Diseases 0.000 claims description 2
- 102100037106 Merlin Human genes 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 206010002224 anaplastic astrocytoma Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 230000003394 haemopoietic effect Effects 0.000 claims description 2
- 208000022080 low-grade astrocytoma Diseases 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 230000002611 ovarian Effects 0.000 claims description 2
- 210000001550 testis Anatomy 0.000 claims description 2
- 210000001541 thymus gland Anatomy 0.000 claims description 2
- 102000013609 MutL Protein Homolog 1 Human genes 0.000 claims 1
- 102000011117 Transforming Growth Factor beta2 Human genes 0.000 claims 1
- 101800000304 Transforming growth factor beta-2 Proteins 0.000 claims 1
- 239000013522 chelant Substances 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 238000007855 methylation-specific PCR Methods 0.000 abstract description 77
- 230000007067 DNA methylation Effects 0.000 abstract description 7
- 206010028980 Neoplasm Diseases 0.000 description 50
- 238000004458 analytical method Methods 0.000 description 35
- 238000006243 chemical reaction Methods 0.000 description 30
- 108700028369 Alleles Proteins 0.000 description 28
- 238000012163 sequencing technique Methods 0.000 description 26
- 201000011510 cancer Diseases 0.000 description 24
- 229940088598 enzyme Drugs 0.000 description 16
- 108091029430 CpG site Proteins 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 14
- 230000004048 modification Effects 0.000 description 14
- 238000012986 modification Methods 0.000 description 14
- 239000000203 mixture Substances 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 230000000692 anti-sense effect Effects 0.000 description 11
- 230000000295 complement effect Effects 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- 239000000499 gel Substances 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 238000006116 polymerization reaction Methods 0.000 description 9
- 102000000905 Cadherin Human genes 0.000 description 8
- 108050007957 Cadherin Proteins 0.000 description 8
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 238000003018 immunoassay Methods 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 230000002103 transcriptional effect Effects 0.000 description 7
- 101001081170 Homo sapiens Humanin-like 12 Proteins 0.000 description 6
- 102100027737 Humanin-like 12 Human genes 0.000 description 6
- 238000012408 PCR amplification Methods 0.000 description 6
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 6
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
- 238000007901 in situ hybridization Methods 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 229920002401 polyacrylamide Polymers 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 208000032818 Microsatellite Instability Diseases 0.000 description 5
- 238000002105 Southern blotting Methods 0.000 description 5
- 238000007385 chemical modification Methods 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 230000019975 dosage compensation by inactivation of X chromosome Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000011065 in-situ storage Methods 0.000 description 5
- 230000002779 inactivation Effects 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108010017826 DNA Polymerase I Proteins 0.000 description 4
- 102000004594 DNA Polymerase I Human genes 0.000 description 4
- 102100028843 DNA mismatch repair protein Mlh1 Human genes 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 description 4
- 108010006785 Taq Polymerase Proteins 0.000 description 4
- 230000001594 aberrant effect Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- 230000001613 neoplastic effect Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- 108060004795 Methyltransferase Proteins 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 230000030279 gene silencing Effects 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- 241000972773 Aulopiformes Species 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 2
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 101000645296 Homo sapiens Metalloproteinase inhibitor 2 Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102100025825 Methylated-DNA-protein-cysteine methyltransferase Human genes 0.000 description 2
- 102000001218 Rec A Recombinases Human genes 0.000 description 2
- 108010055016 Rec A Recombinases Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 108091005735 TGF-beta receptors Proteins 0.000 description 2
- 102000005876 Tissue Inhibitor of Metalloproteinases Human genes 0.000 description 2
- 108010005246 Tissue Inhibitor of Metalloproteinases Proteins 0.000 description 2
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003850 cellular structure Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000002059 diagnostic imaging Methods 0.000 description 2
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 2
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 229940029575 guanosine Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 108040008770 methylated-DNA-[protein]-cysteine S-methyltransferase activity proteins Proteins 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000005298 paramagnetic effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- BAAVRTJSLCSMNM-CMOCDZPBSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]pentanedioic acid Chemical compound C([C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 BAAVRTJSLCSMNM-CMOCDZPBSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- 101150028074 2 gene Proteins 0.000 description 1
- GPLIMIJPIZGPIF-UHFFFAOYSA-N 2-hydroxy-1,4-benzoquinone Chemical compound OC1=CC(=O)C=CC1=O GPLIMIJPIZGPIF-UHFFFAOYSA-N 0.000 description 1
- 108020005065 3' Flanking Region Proteins 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 108020005029 5' Flanking Region Proteins 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 229940126074 CDK kinase inhibitor Drugs 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000004435 EPR spectroscopy Methods 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 208000001914 Fragile X syndrome Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 description 1
- 208000035346 Margins of Excision Diseases 0.000 description 1
- 241000087624 Monoclona Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 108700025701 Retinoblastoma Genes Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 102000005354 Tissue Inhibitor of Metalloproteinase-2 Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 101150046474 Vhl gene Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 108700031765 Von Hippel-Lindau Tumor Suppressor Proteins 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 108700029631 X-Linked Genes Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- SWPYNTWPIAZGLT-UHFFFAOYSA-N [amino(ethoxy)phosphanyl]oxyethane Chemical class CCOP(N)OCC SWPYNTWPIAZGLT-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229940025131 amylases Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000002967 competitive immunoassay Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000007911 de novo DNA methylation Effects 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000013198 immunometric assay Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007850 in situ PCR Methods 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000033607 mismatch repair Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 108010021724 tonin Proteins 0.000 description 1
- 230000037426 transcriptional repression Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 108010032276 tyrosyl-glutamyl-tyrosyl-glutamic acid Proteins 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analyzing Materials By The Use Of Fluid Adsorption Or Reactions (AREA)
- Photoreceptors In Electrophotography (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/656,716 US5786146A (en) | 1996-06-03 | 1996-06-03 | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| US08/835,728 US6017704A (en) | 1996-06-03 | 1997-04-11 | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| PCT/US1997/009533 WO1997046705A1 (en) | 1996-06-03 | 1997-06-03 | Methylation specific detection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL127342A0 IL127342A0 (en) | 1999-10-28 |
| IL127342A true IL127342A (en) | 2002-07-25 |
Family
ID=27097252
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12734297A IL127342A (en) | 1996-06-03 | 1997-06-03 | A method for detecting nucleic acid that includes methylated GPC, a kit for using the method and a method for detecting a disease related to the methylation of nucleic acid |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US6017704A (online.php) |
| EP (2) | EP0954608B1 (online.php) |
| JP (2) | JP3612080B2 (online.php) |
| AT (1) | ATE326549T1 (online.php) |
| CA (1) | CA2257104C (online.php) |
| DE (1) | DE69735894T2 (online.php) |
| DK (1) | DK0954608T3 (online.php) |
| ES (1) | ES2264165T3 (online.php) |
| IL (1) | IL127342A (online.php) |
| PT (1) | PT954608E (online.php) |
| WO (1) | WO1997046705A1 (online.php) |
Families Citing this family (316)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6617434B1 (en) | 1996-05-31 | 2003-09-09 | North Shore Long Island Jewish Research Institute | Identificiaton of differentially methylated and mutated nucleic acids |
| US5871917A (en) | 1996-05-31 | 1999-02-16 | North Shore University Hospital Research Corp. | Identification of differentially methylated and mutated nucleic acids |
| US5786146A (en) * | 1996-06-03 | 1998-07-28 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| WO1998056952A1 (en) * | 1997-06-09 | 1998-12-17 | University Of Southern California | A cancer diagnostic method based upon dna methylation differences |
| US6818404B2 (en) | 1997-10-23 | 2004-11-16 | Exact Sciences Corporation | Methods for detecting hypermethylated nucleic acid in heterogeneous biological samples |
| DE19754482A1 (de) * | 1997-11-27 | 1999-07-01 | Epigenomics Gmbh | Verfahren zur Herstellung komplexer DNA-Methylierungs-Fingerabdrücke |
| AUPP312998A0 (en) * | 1998-04-23 | 1998-05-14 | Commonwealth Scientific And Industrial Research Organisation | Diagnostic assay |
| US7700324B1 (en) * | 1998-11-03 | 2010-04-20 | The Johns Hopkins University School Of Medicine | Methylated CpG island amplification (MCA) |
| US6994991B1 (en) | 1998-11-18 | 2006-02-07 | North Shore - Long Island Jewish Research Institute | Identification of differentially methylated multiple drug resistance loci |
| DE19853398C1 (de) * | 1998-11-19 | 2000-03-16 | Epigenomics Gmbh | Verfahren zur Identifikation von Cytosin-Methylierungsmustern in genomischer DNA |
| DE19905082C1 (de) * | 1999-01-29 | 2000-05-18 | Epigenomics Gmbh | Verfahren zur Identifikation von Cytosin-Methylierungsmustern in genomischen DNA-Proben |
| AUPP844899A0 (en) * | 1999-02-01 | 1999-02-25 | University Of Western Australia, The | A method for detecting methylated nucleic acids |
| US7655443B1 (en) * | 1999-05-07 | 2010-02-02 | Siemens Healthcare Diagnostics, Inc. | Nucleic acid sequencing with simultaneous quantitation |
| US6331393B1 (en) * | 1999-05-14 | 2001-12-18 | University Of Southern California | Process for high-throughput DNA methylation analysis |
| US6709818B1 (en) * | 1999-10-13 | 2004-03-23 | The Johns Hopkins University School Of Medicine | Methods of diagnosing and treating hepatic cell proliferative disorders |
| US20030207297A1 (en) * | 1999-10-13 | 2003-11-06 | Hubert Koster | Methods for generating databases and databases for identifying polymorphic genetic markers |
| AU8021500A (en) * | 1999-10-13 | 2001-04-23 | Johns Hopkins University School Of Medicine, The | Methods of diagnosing and treating hepatic cell proliferative disorders |
| US20030190644A1 (en) * | 1999-10-13 | 2003-10-09 | Andreas Braun | Methods for generating databases and databases for identifying polymorphic genetic markers |
| ATE272722T1 (de) * | 1999-11-12 | 2004-08-15 | Epigenomics Ag | Verfahren zur kontrollierbaren durchführung komplexer pcr-amplifikationen |
| DE19957827C2 (de) * | 1999-11-25 | 2003-06-12 | Epigenomics Ag | Verwendung eines Oligomer-Arrays mit PNA- und/oder DNA-Oligomeren auf einer Oberfläche |
| US20030170649A1 (en) * | 1999-12-03 | 2003-09-11 | Haas Oskar A. | Method for detecting and evaluating a potentially aberrantly methylated dna region on the x chromosome, or the clonality |
| DE19959691A1 (de) * | 1999-12-06 | 2001-08-16 | Epigenomics Ag | Verfahren zur parallelen Detektions des Methylierungszustandes von genomischer DNA |
| GB9929720D0 (en) * | 1999-12-17 | 2000-02-09 | Zeneca Ltd | Diagnostic method |
| US8076063B2 (en) | 2000-02-07 | 2011-12-13 | Illumina, Inc. | Multiplexed methylation detection methods |
| US7582420B2 (en) | 2001-07-12 | 2009-09-01 | Illumina, Inc. | Multiplex nucleic acid reactions |
| US7611869B2 (en) | 2000-02-07 | 2009-11-03 | Illumina, Inc. | Multiplexed methylation detection methods |
| US7955794B2 (en) | 2000-09-21 | 2011-06-07 | Illumina, Inc. | Multiplex nucleic acid reactions |
| DE10010282B4 (de) | 2000-02-25 | 2006-11-16 | Epigenomics Ag | Verfahren zur Detektion von Cytosin-Methylierung in DNA Proben |
| DE10013847A1 (de) * | 2000-03-15 | 2001-09-27 | Epigenomics Ag | Oligonukleotide oder PNA-Oligomere und Verfahren zur parallelen Detektion des Methylierungszustandes genomischer DNA |
| WO2001077377A2 (en) * | 2000-04-06 | 2001-10-18 | Epigenomics Ag | Diagnosis of diseases associated with dna replication by assessing dna methylation |
| US20040006036A1 (en) * | 2000-04-12 | 2004-01-08 | Gmr, A Delaware Corporation | Silencing transcription by methylation |
| DE10029915B4 (de) * | 2000-06-19 | 2005-06-16 | Epigenomics Ag | Verfahren zum Nachweis von Cytosin-Methylierungen |
| AU2001276371A1 (en) * | 2000-06-30 | 2002-01-14 | Epigenomics Ag | Method and nucleic acids for analysing the methylation of genes implicated pharmacogenomics |
| CA2312051A1 (en) * | 2000-07-13 | 2002-01-13 | Quebepharma Inc. | Methylated nucleotide regulation of gene expression |
| DE10038733A1 (de) * | 2000-08-02 | 2002-02-21 | Epigenomics Ag | Verfahren zur Altersbestimmung von Individuen |
| WO2002014557A1 (en) | 2000-08-15 | 2002-02-21 | The Johns Hopkins University School Of Medecine | Diagnosis and treatment of tumor-suppressor associated disorders |
| US7214485B2 (en) * | 2000-08-25 | 2007-05-08 | Lovelace Respiratory Research Institute | Nested methylation-specific polymerase chain reaction cancer detection method |
| EP1320745A4 (en) * | 2000-09-01 | 2008-10-01 | Applera Corp | SYSTEM AND METHOD FOR TEMPERATURE GRADIENT CAPILLARY ELECTROPHORESIS |
| AU2001296511A1 (en) * | 2000-09-29 | 2002-04-08 | The Johns Hopkins University School Of Medicine | Method of predicting the clinical response to chemotherapeutic treatment with alkylating agents |
| DE10050942B4 (de) * | 2000-10-10 | 2005-11-17 | Epigenomics Ag | Verfahren zum Nachweis von Cytosin-Methylierungen |
| AU2002214569A1 (en) * | 2000-10-11 | 2002-04-22 | Spectrumedix Corporation | System and method for determining the presence of methylated cytosines in polynucleotides |
| GB0025913D0 (en) | 2000-10-23 | 2000-12-06 | Guldberg Per | Materials and methods relating to nucleic acid amplification and profiling |
| JP2004512050A (ja) * | 2000-10-23 | 2004-04-22 | キャンサー・リサーチ・テクノロジー・リミテッド | 核酸の増幅およびプロファイリングに関連する物質および方法 |
| JP2004535757A (ja) * | 2000-11-08 | 2004-12-02 | ユニバーシティ・オブ・サザン・カリフォルニア | ヘミメチル化の検出及び定量のための新規アッセイ法 |
| DE10056802B4 (de) * | 2000-11-14 | 2005-06-16 | Epigenomics Ag | Verfahren zur Detektion von Methylierungszuständen zur toxikologischen Diagnostik |
| US6756200B2 (en) * | 2001-01-26 | 2004-06-29 | The Johns Hopkins University School Of Medicine | Aberrantly methylated genes as markers of breast malignancy |
| US6893820B1 (en) * | 2001-01-31 | 2005-05-17 | The Ohio State University Research Foundation | Detection of methylated CpG rich sequences diagnostic for malignant cells |
| AU2002318336A1 (en) * | 2001-06-08 | 2002-12-23 | U.S. Genomics, Inc. | Methods and products for analyzing nucleic acids based on methylation status |
| DE10128509A1 (de) * | 2001-06-14 | 2003-01-02 | Epigenomics Ag | Verfahren und Nukleinsäuren für die Differenzierung von Prostata- und Nierenkarzinomen |
| DE10128508A1 (de) * | 2001-06-14 | 2003-02-06 | Epigenomics Ag | Verfahren und Nukleinsäuren für die Differenzierung von Prostata-Tumoren |
| JP2005508885A (ja) * | 2001-07-31 | 2005-04-07 | ザ ステイト オブ オレゴン， アクティング バイ アンド スルー ザ ステイト ボード オブ ハイヤー エデュケイション オン ビハーフ オブ ザ ユニバーシティー オブ オレゴン | Ｄｎａメチル化の阻害剤 |
| DE10139283A1 (de) * | 2001-08-09 | 2003-03-13 | Epigenomics Ag | Verfahren und Nukleinsäuren zur Analyse von Colon-Krebs |
| US6927028B2 (en) * | 2001-08-31 | 2005-08-09 | Chinese University Of Hong Kong | Non-invasive methods for detecting non-host DNA in a host using epigenetic differences between the host and non-host DNA |
| WO2003031932A2 (en) * | 2001-10-05 | 2003-04-17 | Case Western Reserve University | Methods and compositions for detecting colon cancers |
| DE10151055B4 (de) | 2001-10-05 | 2005-05-25 | Epigenomics Ag | Verfahren zum Nachweis von Cytosin-Methylierung in CpG Inseln |
| WO2003033743A1 (en) * | 2001-10-18 | 2003-04-24 | Spectrumedix Corporation | System and method for temperature gradient capillary electrophoresis |
| JP2005515787A (ja) * | 2001-10-18 | 2005-06-02 | ラブレイス レスピレイトリー リサーチ インスティチュート | 転写因子遺伝子ＰＡＸ５α、ＰＡＸ５β、新規ループヘリックスループタンパク質、新規遺伝子２、およびベータ３遺伝子のプロモーターの異常メチル化による癌のモニタリング |
| US20030099997A1 (en) * | 2001-10-24 | 2003-05-29 | Bestor Timothy H. | Method for gene identification based on differential DNA methylation |
| DE10154317B4 (de) | 2001-10-26 | 2005-06-09 | Epigenomics Ag | Verfahren zum Nachweis von Cytosin-Methylierungen in immobilisierten DNA Proben |
| WO2003044232A1 (en) * | 2001-11-16 | 2003-05-30 | The Johns Hopkins University School Of Medicine | Method of detection of prostate cancer |
| US20110151438A9 (en) * | 2001-11-19 | 2011-06-23 | Affymetrix, Inc. | Methods of Analysis of Methylation |
| WO2003048332A2 (en) | 2001-11-30 | 2003-06-12 | The Johns Hopkins University | METHODS FOR ANALYZING METHYLATED CpG ISLANDS AND GC RICH REGIONS |
| DE10201138B4 (de) * | 2002-01-08 | 2005-03-10 | Epigenomics Ag | Verfahren zum Nachweis von Cytosin-Methylierungsmustern durch exponentielle Ligation hybridisierter Sondenoligonukleotide (MLA) |
| AU2003212878A1 (en) * | 2002-01-30 | 2003-09-02 | Epigenomics Ag | Identification of cell differentiation states based on methylation patterns |
| WO2003071252A2 (en) * | 2002-02-15 | 2003-08-28 | Exact Sciences Corporation | Methods for analysis of molecular events |
| KR100470221B1 (ko) * | 2002-02-20 | 2005-02-05 | 굿젠 주식회사 | 유전자 프로모터 ＣｐＧ 아일랜드의 메틸화 여부를분석하는 염기서열분석형 올리고뉴클레오타이드칩, 이의제조방법 및 이를 이용한 암 검색방법 |
| EP1340818A1 (en) * | 2002-02-27 | 2003-09-03 | Epigenomics AG | Method and nucleic acids for the analysis of a colon cell proliferative disorder |
| ES2253461T3 (es) * | 2002-03-05 | 2006-06-01 | Epigenomics Ag | Procedimiento y dispositivo para la determinacion de la especificidad del tejido y del adn que flota libre en tejidos corporales. |
| WO2003076666A1 (en) * | 2002-03-08 | 2003-09-18 | Naxcor | Compositions and methods for detecting nucleic acid methylation |
| WO2003083107A1 (en) * | 2002-03-25 | 2003-10-09 | The Board Of Trustees Of The University Of Arkansas | Cpg retrieval of dna from formalin-fixed pathology specimen for promoter methylation analysis |
| US6872530B2 (en) * | 2002-04-24 | 2005-03-29 | Spectrumedix, Llc | Method for determining the presence of DNA variants using peptide nucleic acid probes |
| US7432342B2 (en) * | 2002-05-03 | 2008-10-07 | Sequenom, Inc. | Kinase anchor protein muteins, peptides thereof and related documents |
| WO2003104427A2 (en) * | 2002-06-05 | 2003-12-18 | Case Western Reserve University | Methods and compositions for detecting cancers |
| AU2003244135A1 (en) * | 2002-06-21 | 2004-01-06 | Hinode Co, . Ltd. | Device for removing raindrops on umrella and system for promoting installation of the device |
| JP4384603B2 (ja) * | 2002-06-26 | 2009-12-16 | コールド スプリング ハーバー ラボラトリー | メチル化プロファイルを測定するための方法および組成物 |
| AU2003256579A1 (en) * | 2002-07-16 | 2004-02-02 | Spectrumedix Llc | Method and system for comparative genomics for organisms using temperature gradient electrophoresis |
| CA2500255A1 (en) | 2002-10-01 | 2004-04-29 | Epigenomics Ag | Method and nucleic acids for the treatment of breast cell proliferative disorders |
| US7666589B2 (en) * | 2002-10-02 | 2010-02-23 | Northwestern University | Methylation profile of breast cancer |
| CA2442438C (en) | 2002-10-04 | 2012-06-19 | Nisshinbo Industries, Inc. | Oligonucleotide-immobilized substrate for detecting methylation |
| CA2507189C (en) | 2002-11-27 | 2018-06-12 | Sequenom, Inc. | Fragmentation-based methods and systems for sequence variation detection and discovery |
| US20060094016A1 (en) * | 2002-12-02 | 2006-05-04 | Niall Gormley | Determination of methylation of nucleic acid sequences |
| US20040146868A1 (en) * | 2003-01-24 | 2004-07-29 | Epigenomics Ag | Methods and nucleic acids for the analysis of CpG dinucleotide methylation status associated with the development of peripheral zone prostate cancer |
| AU2003900368A0 (en) * | 2003-01-24 | 2003-02-13 | Human Genetic Signatures Pty Ltd | Assay for nucleic acid molecules |
| DE10304219B3 (de) * | 2003-01-30 | 2004-08-19 | Epigenomics Ag | Verfahren zum Nachweis von Cytosin-Methylierungsmustern mit hoher Sensitivität |
| US20070141570A1 (en) * | 2003-03-07 | 2007-06-21 | Sequenom, Inc. | Association of polymorphic kinase anchor proteins with cardiac phenotypes and related methods |
| EP1604013A4 (en) * | 2003-03-17 | 2009-02-11 | Univ Johns Hopkins | ANOMALALLY METHYLATED GENES IN PANCREATIC CANCER |
| WO2004087957A2 (en) * | 2003-04-03 | 2004-10-14 | Oncomethylome Sciences S.A. | Hypermethylated genes and cervical cancer |
| US20040203004A1 (en) * | 2003-04-10 | 2004-10-14 | Bernard Hans Ulrich | Diagnostic apparatus and method |
| CA2523490A1 (en) * | 2003-04-25 | 2004-11-11 | Sequenom, Inc. | Fragmentation-based methods and systems for de novo sequencing |
| US7288373B2 (en) * | 2003-05-02 | 2007-10-30 | Human Genetic Signatures Pty Ltd. | Treatment of methylated nucleic acid |
| US20050009059A1 (en) * | 2003-05-07 | 2005-01-13 | Affymetrix, Inc. | Analysis of methylation status using oligonucleotide arrays |
| US20050026183A1 (en) * | 2003-05-15 | 2005-02-03 | Jian-Bing Fan | Methods and compositions for diagnosing conditions associated with specific DNA methylation patterns |
| US8150627B2 (en) | 2003-05-15 | 2012-04-03 | Illumina, Inc. | Methods and compositions for diagnosing lung cancer with specific DNA methylation patterns |
| US8150626B2 (en) * | 2003-05-15 | 2012-04-03 | Illumina, Inc. | Methods and compositions for diagnosing lung cancer with specific DNA methylation patterns |
| WO2004111266A1 (en) * | 2003-06-17 | 2004-12-23 | Human Genetic Signatures Pty Ltd | Methods for genome amplification |
| WO2005001141A2 (en) * | 2003-06-23 | 2005-01-06 | Epigenomics Ag | Methods and nucleic acids for analyses of colorectal cell proliferative disorders |
| ES2546644T3 (es) | 2003-06-23 | 2015-09-25 | Epigenomics Ag | Métodos y ácidos nucleicos para el análisis de trastornos proliferativos de células colorrectales |
| US8163488B2 (en) | 2003-06-23 | 2012-04-24 | Epigenomics Ag | Methods and nucleic acids for analysis of colon proliferative disorders |
| US20040265833A1 (en) * | 2003-06-23 | 2004-12-30 | Cathy Lofton-Day | Methods and nucleic acids for the analysis of colorectal cell proliferative disorders |
| WO2004113567A2 (en) * | 2003-06-24 | 2004-12-29 | Epigenomics Ag | Improved heavymethyl assay for the methylation analysis of the gstpi gene |
| US7303879B2 (en) * | 2003-07-31 | 2007-12-04 | Applera Corporation | Determination of SNP allelic frequencies using temperature gradient electrophoresis |
| US20050123944A1 (en) * | 2003-08-01 | 2005-06-09 | U.S. Genomics, Inc. | Methods and compositions related to the use of sequence-specific endonucleases for analyzing nucleic acids under non-cleaving conditions |
| US20060183128A1 (en) * | 2003-08-12 | 2006-08-17 | Epigenomics Ag | Methods and compositions for differentiating tissues for cell types using epigenetic markers |
| US8415100B2 (en) | 2003-08-14 | 2013-04-09 | Case Western Reserve University | Methods and compositions for detecting gastrointestinal and other cancers |
| EP1660683B1 (en) * | 2003-08-14 | 2017-04-19 | Case Western Reserve University | Methods and compositions for detecting colon cancers |
| DE10338308B4 (de) | 2003-08-15 | 2006-10-19 | Epigenomics Ag | Verfahren zum Nachweis von Cytosin-Methylierungen in DNA |
| US7198900B2 (en) | 2003-08-29 | 2007-04-03 | Applera Corporation | Multiplex detection compositions, methods, and kits |
| WO2005021743A1 (ja) * | 2003-08-29 | 2005-03-10 | Tanaka, Noriaki | 核酸増幅用プライマー及びこれを用いた大腸癌の検査方法 |
| EP1668148B1 (en) * | 2003-09-04 | 2008-12-31 | Human Genetic Signatures PTY Ltd. | Nucleic acid detection assay |
| WO2005024068A2 (en) * | 2003-09-05 | 2005-03-17 | Sequenom, Inc. | Allele-specific sequence variation analysis |
| DE10348407A1 (de) * | 2003-10-17 | 2005-05-19 | Widschwendter, Martin, Prof. | Prognostische und diagnostische Marker für Zell-proliferative Erkrankungen von Brustgeweben |
| ATE553218T1 (de) * | 2003-10-21 | 2012-04-15 | Orion Genomics Llc | Differentielle enzymatische fragmetierung |
| EP3269826B1 (en) | 2003-12-01 | 2020-03-11 | Epigenomics AG | Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders |
| JP2007513621A (ja) | 2003-12-11 | 2007-05-31 | エピゲノミクス アーゲー | 乳房細胞増殖性障害の改良された処置のための方法および核酸 |
| DE102004002257B4 (de) * | 2004-01-09 | 2006-11-09 | Epigenomics Ag | Verfahren zur Untersuchung von Cytosin-Methylierungen in DNA mit Hilfe von DNA-Reparaturenzymen |
| WO2005076837A2 (en) * | 2004-02-10 | 2005-08-25 | Cornell Research Foundation, Inc. | Method for detection of promoter methylation status |
| WO2005085477A1 (en) * | 2004-03-02 | 2005-09-15 | Orion Genomics Llc | Differential enzymatic fragmentation by whole genome amplification |
| US7608394B2 (en) | 2004-03-26 | 2009-10-27 | Sequenom, Inc. | Methods and compositions for phenotype identification based on nucleic acid methylation |
| US9249456B2 (en) * | 2004-03-26 | 2016-02-02 | Agena Bioscience, Inc. | Base specific cleavage of methylation-specific amplification products in combination with mass analysis |
| US8168777B2 (en) | 2004-04-29 | 2012-05-01 | Human Genetic Signatures Pty. Ltd. | Bisulphite reagent treatment of nucleic acid |
| US20080241827A1 (en) * | 2004-05-10 | 2008-10-02 | Exact Sciences Corporation | Methods For Detecting A Mutant Nucleic Acid |
| WO2005118872A2 (en) * | 2004-06-01 | 2005-12-15 | The Regents Of The University Of Michigan | Methods and kits for diagnosing or monitoring autoimmune and chronic inflammatory diseases |
| EP1778865A1 (en) * | 2004-06-23 | 2007-05-02 | Epigenomics AG | Methods and nucleic acids for the detection of metastasis of colon cell proliferative disorders |
| EP1961827A3 (en) | 2004-07-18 | 2008-09-17 | Epigenomics AG | Epigenetic methods and nucleic acids for the detection of breast cell proliferative disorders |
| US7981607B2 (en) * | 2004-08-27 | 2011-07-19 | Esoterix Genetic Laboratories LLC | Method for detecting recombinant event |
| CN101072882A (zh) * | 2004-09-10 | 2007-11-14 | 塞昆纳姆股份有限公司 | 用于核酸长程序列分析的方法 |
| JP4980219B2 (ja) * | 2004-09-10 | 2012-07-18 | ヒューマン ジェネティック シグネチャーズ ピーティーワイ リミテッド | インターカレート型擬似ヌクレオチド（ｉｐｎ）を含有するインターカレーティング核酸（ｉｎａ）を含む増幅ブロッカー |
| KR100617649B1 (ko) | 2004-09-24 | 2006-09-04 | (주)지노믹트리 | 대장암 특이적 발현감소 유전자의 메틸화된 프로모터를 함유하는 암 진단용 조성물 및 그 용도 |
| US20080171318A1 (en) * | 2004-09-30 | 2008-07-17 | Epigenomics Ag | Epigenetic Methods and Nucleic Acids for the Detection of Lung Cell Proliferative Disorders |
| US9109256B2 (en) | 2004-10-27 | 2015-08-18 | Esoterix Genetic Laboratories, Llc | Method for monitoring disease progression or recurrence |
| BRPI0517976A (pt) * | 2004-11-09 | 2008-10-21 | Schering Corp | métodos de tratamento |
| CA2593546A1 (en) * | 2004-12-02 | 2006-07-06 | Epigenomics Ag | Methods and nucleic acids for the analysis of gene expression associated with the prognosis of prostate cell proliferative disorders |
| EP1838307A1 (en) * | 2004-12-02 | 2007-10-03 | Schering Corporation | Methods of using temozolomide formulation intrathecally in the treatment of cancers |
| NZ555620A (en) * | 2004-12-03 | 2008-08-29 | Human Genetic Signatures Pty | Methods for simplifying microbial nucleic acids by chemical modification of cytosines |
| CA2592993C (en) | 2004-12-13 | 2013-06-18 | National University Corporation Okayama University | Method for detecting methylation in genes and method for examining neoplasm through detecting methylation in genes |
| US20060134650A1 (en) * | 2004-12-21 | 2006-06-22 | Illumina, Inc. | Methylation-sensitive restriction enzyme endonuclease method of whole genome methylation analysis |
| JP2008524990A (ja) * | 2004-12-23 | 2008-07-17 | ヒューマン ジェネティック シグネチャーズ ピーティーワイ リミテッド | ヒトパピローマウイルスの検出 |
| US7588894B2 (en) | 2005-02-01 | 2009-09-15 | John Wayne Cancern Institute | Use of ID4 for diagnosis and treatment of cancer |
| EP1853727A4 (en) | 2005-02-14 | 2010-01-06 | Univ Johns Hopkins | NEOPLASIE SCREENING COMPOSITIONS AND USE METHOD |
| WO2006094149A2 (en) * | 2005-03-01 | 2006-09-08 | Exact Sciences Corporation | Methods and compositions for detecting adenoma |
| KR100735045B1 (ko) | 2005-04-07 | 2007-07-03 | (주) 차바이오텍 | 마우스의 ｂ1 서열을 이용한 ｄｎａ 메틸화를 측정하는방법 및 이를 이용한 항암제의 항암활성 측정법 |
| CA2606296C (en) | 2005-04-15 | 2019-05-21 | Epigenomics Ag | Methods and nucleic acids for analyses of cellular proliferative disorders |
| WO2007044071A2 (en) * | 2005-04-21 | 2007-04-19 | Exact Sciences Corporation | Analysis of heterogeneous nucleic acid samples |
| EP2386654A1 (en) | 2005-05-02 | 2011-11-16 | University of Southern California | DNA Methylation markers associated with the CpG island methylator phenotype (cimp) in human colorectal cancer |
| EP1883707B1 (en) * | 2005-05-26 | 2014-04-09 | Human Genetic Signatures PTY Ltd | Isothermal strand displacement amplification using primers containing a non-regular base |
| US7439024B2 (en) | 2005-06-01 | 2008-10-21 | The United States Of America As Represented By The Department Of Veterans Affairs | Methods and kits for diagnosing or monitoring autoimmune and chronic inflammatory diseases |
| US20070037184A1 (en) * | 2005-06-16 | 2007-02-15 | Applera Corporation | Methods and kits for evaluating dna methylation |
| US20060286577A1 (en) * | 2005-06-17 | 2006-12-21 | Xiyu Jia | Methods for detection of methylated DNA |
| US20070087360A1 (en) * | 2005-06-20 | 2007-04-19 | Boyd Victoria L | Methods and compositions for detecting nucleotides |
| US20060292585A1 (en) * | 2005-06-24 | 2006-12-28 | Affymetrix, Inc. | Analysis of methylation using nucleic acid arrays |
| JP2009501024A (ja) * | 2005-07-12 | 2009-01-15 | テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | 癌の診断及び治療における遺伝的及びエピジェネティックな変化 |
| EP1904649A2 (en) * | 2005-07-18 | 2008-04-02 | Epigenomics AG | Compositions and methods for cancer diagnostics comprising pan-cancer markers |
| CN101292046B (zh) * | 2005-09-14 | 2013-03-13 | 人类遗传标记控股有限公司 | 健康状态的测定法 |
| US20070059753A1 (en) * | 2005-09-15 | 2007-03-15 | Tatiana Vener | Detecting gene methylation |
| ES2404066T3 (es) * | 2005-09-21 | 2013-05-23 | Epigenomics Ag | Marcadores para la predicción del resultado de un tratamiento con antraciclina |
| US20090191548A1 (en) | 2005-09-29 | 2009-07-30 | Epigenomics Ag | Methods and nucleic acids for the analysis of gene expression associated with tissue classification |
| US20080254470A1 (en) * | 2005-10-03 | 2008-10-16 | Epigenomics Ag | Methods and Nucleic Acids For the Analysis of Gene Expression Associated With the Prognosis of Cell Proliferative Disorders |
| US20090042195A1 (en) * | 2005-10-07 | 2009-02-12 | Bradford Coffee | Methods and systems for screening for and diagnosing dna methylation associated abnormalities and sex chromosome aneuploidies |
| WO2007042041A1 (en) * | 2005-10-12 | 2007-04-19 | Scanvaegt International A/S | Device for transfer of items |
| US20070087358A1 (en) * | 2005-10-19 | 2007-04-19 | Melanie Ehrlich | Methods for diagnosing cancer based on DNA methylation status in NBL2 |
| EP1951911A2 (en) | 2005-11-08 | 2008-08-06 | Euclid Diagnostics LLC | Materials and methods for assaying for methylation of cpg islands associated with genes in the evaluation of cancer |
| EP1969139A1 (en) * | 2005-11-17 | 2008-09-17 | Epigenomics AG | Method for the determination of the dna methylation level of a cpg position in identical cells within a tissue sample |
| AU2007207465B2 (en) | 2006-01-18 | 2012-12-06 | Merck Patent Gmbh | Specific therapy using integrin ligands for treating cancer |
| US7820385B2 (en) * | 2006-03-22 | 2010-10-26 | The United States Of America As Represented By The Department Of Health And Human Services, Centers For Disease Control And Prevention | Method for retaining methylation pattern in globally amplified DNA |
| EP1840224A1 (en) | 2006-03-29 | 2007-10-03 | Pangaea Biotech, S.A. | Method of predicting survival of a non-small-cell lung cancer patient to a chemotherapeutic treatment |
| EP2004860A4 (en) * | 2006-03-29 | 2009-12-30 | Wayne John Cancer Inst | METHYLATION OF THE OESTROGEN ALPHA RECEPTOR AND USES THEREOF |
| US7901882B2 (en) | 2006-03-31 | 2011-03-08 | Affymetrix, Inc. | Analysis of methylation using nucleic acid arrays |
| US20090317810A1 (en) * | 2006-04-17 | 2009-12-24 | Epigenomics Ag | Methods and nucleic acids for the detection of colorectal cell proliferative disorders |
| EP2484778A3 (en) | 2006-04-17 | 2012-10-10 | Epigenomics AG | Methods and nucleic acids for the detection of colorectal cell proliferative disorders |
| WO2007133496A2 (en) * | 2006-05-09 | 2007-11-22 | Schering Corporation | Development of a novel assay for mgmt (methyl guanine transferase) |
| US20080003609A1 (en) * | 2006-05-10 | 2008-01-03 | The Cleveland Clinic Foundation | Method of detecting bladder urothelial carcinoma |
| WO2007140319A1 (en) * | 2006-05-26 | 2007-12-06 | Meltzer Stephen J | Methylated promoters as biomarkers of colon cancer |
| KR100761031B1 (ko) | 2006-05-27 | 2007-10-04 | 김연수 | 디엔에이 메틸화 현상을 이용한 암 진단용 키트 |
| US20080050738A1 (en) * | 2006-05-31 | 2008-02-28 | Human Genetic Signatures Pty Ltd. | Detection of target nucleic acid |
| CA2656807A1 (en) * | 2006-07-14 | 2008-01-24 | Oncomethylome Sciences, S.A. | Early detection and prognosis of colon cancers |
| ES2546182T3 (es) | 2006-07-21 | 2015-09-21 | Epigenomics Ag | Métodos y kits para análisis de metilación en trastornos proliferativos celulares colorrectales |
| US20100278772A1 (en) | 2006-11-20 | 2010-11-04 | The Johns Hopkins University | Dna methylation markers and methods of use |
| US20100203514A1 (en) | 2006-11-24 | 2010-08-12 | Sledziewski Andrew Z | Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders |
| BRPI0806596A2 (pt) | 2007-01-18 | 2013-07-23 | Merck Patent Ges Mit Berchraenkter Haftung | medicamento e terapia especÍfica usando-se ligantes de integrina para o tratamento de cÂncer |
| US20090203011A1 (en) * | 2007-01-19 | 2009-08-13 | Epigenomics Ag | Methods and nucleic acids for analyses of cell proliferative disorders |
| DK2258871T3 (da) | 2007-01-19 | 2014-08-11 | Epigenomics Ag | Fremgangsmåder og nukleinsyrer til analyse af celleproliferative lidelser |
| WO2008096146A1 (en) | 2007-02-07 | 2008-08-14 | Solexa Limited | Preparation of templates for methylation analysis |
| US20100092972A1 (en) * | 2007-03-16 | 2010-04-15 | Human Genetic Signatures Pty Ltd. | Assay for gene expression |
| WO2008128198A2 (en) | 2007-04-12 | 2008-10-23 | Usc Stevens - University Of Southern California | Dna methylation analysis by digital bisulfite genomic sequencing and digital methylight |
| CA2685376A1 (en) * | 2007-04-25 | 2008-11-06 | John Wayne Cancer Institute | Use of methylated or unmethylated line-1 dna as a cancer marker |
| NZ580982A (en) | 2007-05-08 | 2012-05-25 | Schering Corp | Methods of treatment using intravenous formulations comprising temozolomide |
| BRPI0811271A2 (pt) * | 2007-05-31 | 2015-01-20 | Monsanto Technology Llc | Polimorfismos da soja e processos de genotipagem |
| US8673563B2 (en) | 2007-06-08 | 2014-03-18 | Bio-Dixam, Llc | Amplification method of methylated or unmethylated nucleic acid |
| DK2198042T3 (en) | 2007-09-17 | 2017-01-23 | Mdxhealth Sa | New markers for bladder cancer detection |
| WO2009037635A2 (en) | 2007-09-17 | 2009-03-26 | Koninklijke Philips Electronics N. V. | Method for the analysis of breast cancer disorders |
| RU2511408C2 (ru) | 2007-09-17 | 2014-04-10 | Конинклейке Филипс Электроникс Н.В. | Способ анализа нарушений, связанных с раком яичников |
| AU2008329549B2 (en) * | 2007-11-27 | 2013-08-22 | Human Genetic Signatures Pty Ltd | Enzymes for amplification and copying bisulphite modified nucleic acids |
| AU2008334901A1 (en) | 2007-12-11 | 2009-06-18 | Epigenomics Ag | Methods and nucleic acids for analyses of lung carcinoma |
| JP2011505845A (ja) * | 2007-12-20 | 2011-03-03 | ヒューマン ジェネティック シグネチャーズ ピーティーワイ リミテッド | 核酸増幅に伴う汚染物質の排除 |
| WO2009089598A2 (en) * | 2008-01-18 | 2009-07-23 | Katholieke Universiteit Leuven | Msmb-gene methylation based diagnosis, staging and prognosis of prostate cancer |
| EP2250287B1 (en) | 2008-02-19 | 2013-09-18 | MDxHealth SA | Detection and prognosis of lung cancer |
| CA2718092C (en) | 2008-03-21 | 2019-03-19 | Oncomethylome Sciences S.A. | Detection and prognosis of cervical cancer |
| WO2009128453A1 (ja) * | 2008-04-14 | 2009-10-22 | 学校法人日本大学 | 増殖性疾患の検出方法 |
| BRPI0913578A2 (pt) | 2008-05-14 | 2017-06-06 | Dermtech Int | diagnose de melanoma e lentigo solar por análise de ácido nucléico |
| EP2304057B1 (en) | 2008-06-17 | 2014-09-17 | Signature Diagnostics AG | Method for the detection of ovarian cancer |
| US8541207B2 (en) | 2008-10-22 | 2013-09-24 | Illumina, Inc. | Preservation of information related to genomic DNA methylation |
| CN102257161A (zh) | 2008-12-18 | 2011-11-23 | 皇家飞利浦电子股份有限公司 | 用于检测dna甲基化模式的方法 |
| DK2210954T3 (da) | 2009-01-22 | 2011-10-10 | Univ Duesseldorf H Heine | Bestemmelse af DNA-methyleringsniveau |
| EP2394170B1 (en) | 2009-02-03 | 2015-04-01 | MDxHealth SA | Methods of detecting colorectal cancer |
| EP2406393B1 (en) | 2009-03-13 | 2016-05-04 | MDxHealth SA | Novel markers for bladder cancer detection |
| EP2408933A2 (en) | 2009-03-17 | 2012-01-25 | MDxHealth SA | Improved detection of gene expression |
| US20120101023A1 (en) | 2009-04-20 | 2012-04-26 | Erasmus University Medical Center Rotterdam | Method of diagnosing bladder cancer |
| EP2445534A2 (en) | 2009-05-25 | 2012-05-02 | Merck Patent GmbH | Continuous administration of cilengitide in cancer treatments |
| US20120184447A1 (en) | 2009-06-26 | 2012-07-19 | Reinhold Wasserkort | Methods and Nucleic Acids for Analysis of Bladder Cell Proliferative Disorders |
| US9624530B2 (en) * | 2009-08-03 | 2017-04-18 | Epigenomics Ag | Methods for preservation of genomic DNA sequence complexity |
| US8642271B2 (en) * | 2009-08-27 | 2014-02-04 | Case Western Reserve University | Aberrant methylation of C6Orf150 DNA sequences in human colorectal cancer |
| WO2011036173A1 (en) | 2009-09-24 | 2011-03-31 | Oncomethylome Sciences S.A. | Detection and prognosis of cervical cancer |
| US8399138B2 (en) * | 2009-10-14 | 2013-03-19 | GM Global Technology Operations LLC | Liquid rechargeable lithium ion battery |
| US20130143210A1 (en) | 2009-10-28 | 2013-06-06 | Fabian Model | Method for the prognosis of ovarian carcinoma |
| US20110104695A1 (en) | 2009-11-05 | 2011-05-05 | Epigenomics Ag | Methods of predicting therapeutic efficacy of cancer therapy |
| EP2504448B1 (en) * | 2009-11-25 | 2016-10-19 | Bio-Rad Laboratories, Inc. | Methods and compositions for detecting genetic material |
| WO2011112845A2 (en) * | 2010-03-11 | 2011-09-15 | Board Of Regents, The University Of Texas System | Methods and compositions related to a multi-methylation assay to predict patient outcome |
| WO2011135058A2 (en) | 2010-04-30 | 2011-11-03 | Mdxhealth Sa | Methods for detecting epigenetic modifications |
| US20130052644A1 (en) | 2010-04-30 | 2013-02-28 | Baltazar Gomez-Mancilla | Predictive Markers Useful in the Treatment of Fragile X Syndrome (FXS) |
| DK2576832T3 (en) | 2010-05-25 | 2016-06-20 | Univ Johns Hopkins | CONFIGURATIONS AND METHODS FOR DETECTION OF neoplasia |
| AU2011278700A1 (en) | 2010-07-16 | 2013-02-28 | Merck Patent Gmbh | Peptide for use in the treatment of breast cancer and/or bone metastases |
| US8916344B2 (en) | 2010-11-15 | 2014-12-23 | Exact Sciences Corporation | Methylation assay |
| US8361720B2 (en) | 2010-11-15 | 2013-01-29 | Exact Sciences Corporation | Real time cleavage assay |
| JP2014519310A (ja) | 2011-02-02 | 2014-08-14 | エクザクト サイエンシーズ コーポレイション | Ｄｎａメチル化のデジタル配列分析 |
| EP2673380B1 (en) | 2011-02-09 | 2018-12-12 | Bio-Rad Laboratories, Inc. | Analysis of nucleic acids |
| US10435743B2 (en) | 2011-05-20 | 2019-10-08 | The Regents Of The University Of California | Method to estimate age of individual based on epigenetic markers in biological sample |
| JP6397762B2 (ja) | 2011-07-08 | 2018-09-26 | エピゲノミクス アーゲー | がん被験体の予後を決定する方法及び核酸 |
| KR101912488B1 (ko) | 2011-09-07 | 2018-10-26 | 휴먼 제네틱 시그너처스 피티와이 엘티디 | 분자 검출 분석법 |
| WO2013084075A2 (en) | 2011-12-06 | 2013-06-13 | Mdxhealth Sa | Methods of detecting mutations and epigenetic changes |
| WO2013096661A1 (en) | 2011-12-22 | 2013-06-27 | Illumina, Inc. | Methylation biomarkers for ovarian cancer |
| WO2013131981A1 (en) | 2012-03-08 | 2013-09-12 | Novartis Ag | Predictive markers useful in the diagnosis and treatment of fragile x syndrome (fxs) |
| US9428813B2 (en) | 2012-03-26 | 2016-08-30 | The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services | DNA methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms |
| EP2644705A1 (en) | 2012-03-30 | 2013-10-02 | RWTH Aachen | Biomarker for bladder cancer |
| EP2844768B1 (en) | 2012-04-30 | 2019-03-13 | Raindance Technologies, Inc. | Digital analyte analysis |
| CA2874407A1 (en) | 2012-05-24 | 2013-11-28 | Fundacio Institut D'investigacio Biomedica De Bellvitge (Idibell) | Method for the identification of the origin of a cancer of unknown primary origin by methylation analysis |
| US10059996B2 (en) | 2012-06-11 | 2018-08-28 | Medizineische Hochschule Hannover | Susceptibility to and stratification for monoaminergic antidepressants |
| WO2014160233A1 (en) | 2013-03-13 | 2014-10-02 | Abbott Molecular Inc. | Systems and methods for isolating nucleic acids |
| ES2859645T3 (es) | 2013-03-14 | 2021-10-04 | Mayo Found Medical Education & Res | Detección de neoplasia |
| JP2016512437A (ja) | 2013-03-14 | 2016-04-28 | アボツト・モレキユラー・インコーポレイテツド | 多重メチル化特異的増幅システムおよび方法 |
| EP2986762B1 (en) | 2013-04-19 | 2019-11-06 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
| CN104250663B (zh) * | 2013-06-27 | 2017-09-15 | 北京大学 | 甲基化CpG岛的高通量测序检测方法 |
| GB201322034D0 (en) | 2013-12-12 | 2014-01-29 | Almac Diagnostics Ltd | Prostate cancer classification |
| WO2015124921A1 (en) | 2014-02-19 | 2015-08-27 | The University Court Of The University Of Edinburgh | Methods and uses for determining the presence of inflammatory bowel disease |
| CN106460046A (zh) | 2014-03-31 | 2017-02-22 | 梅奥医学教育和研究基金会 | 检测结直肠赘生物 |
| WO2015169857A1 (en) | 2014-05-07 | 2015-11-12 | Université Libre de Bruxelles | Breast cancer epigenetic markers useful in anthracycline treatment prognosis |
| US10801067B2 (en) | 2014-05-09 | 2020-10-13 | Eurofins Lifecodexx Gmbh | Detection of DNA that originates from a specific cell-type and related methods |
| EP2942401A1 (en) | 2014-05-09 | 2015-11-11 | Lifecodexx AG | Detection of DNA that originates from a specific cell-type |
| EP2942400A1 (en) | 2014-05-09 | 2015-11-11 | Lifecodexx AG | Multiplex detection of DNA that originates from a specific cell-type |
| US10184154B2 (en) | 2014-09-26 | 2019-01-22 | Mayo Foundation For Medical Education And Research | Detecting cholangiocarcinoma |
| US10465248B2 (en) | 2014-12-12 | 2019-11-05 | Exact Sciences Development Company, Llc | Method of characterizing ZDHHC1 DNA |
| US9984201B2 (en) | 2015-01-18 | 2018-05-29 | Youhealth Biotech, Limited | Method and system for determining cancer status |
| WO2016160454A1 (en) | 2015-03-27 | 2016-10-06 | Exact Sciences Corporation | Detecting esophageal disorders |
| US10683547B2 (en) | 2015-05-29 | 2020-06-16 | Vito Nv | Epigenetic markers for respiratory allergy |
| GB201510684D0 (en) | 2015-06-17 | 2015-08-05 | Almac Diagnostics Ltd | Gene signatures predictive of metastatic disease |
| KR20250172724A (ko) | 2015-08-31 | 2025-12-09 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 위 신생물 검출 방법 |
| EP3162899A1 (en) | 2015-10-29 | 2017-05-03 | Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen | Biomarker for breast cancer |
| KR20250073555A (ko) | 2015-10-30 | 2025-05-27 | 이그잭트 사이언시즈 코포레이션 | 복합 증폭 검출 분석 및 혈장으로부터 dna의 분리 및 검출 방법 |
| HUE050491T2 (hu) | 2015-11-10 | 2020-12-28 | Eurofins Lifecodexx Gmbh | Magzati kromoszomális aneuploidiák kimutatása olyan DNS régiókat alkalmazva, amelyek különbözõképpen vannak metilezve a magzat és a terhes nõstény között |
| CN109072300B (zh) | 2015-12-17 | 2023-01-31 | 伊路敏纳公司 | 区分复杂生物样品中的甲基化水平 |
| US10913986B2 (en) | 2016-02-01 | 2021-02-09 | The Board Of Regents Of The University Of Nebraska | Method of identifying important methylome features and use thereof |
| CN116064796A (zh) | 2016-05-05 | 2023-05-05 | 精密科学公司 | 通过分析甲基化dna来检测肺肿瘤 |
| US11685955B2 (en) | 2016-05-16 | 2023-06-27 | Dimo Dietrich | Method for predicting response of patients with malignant diseases to immunotherapy |
| DE102016005947B3 (de) | 2016-05-16 | 2017-06-08 | Dimo Dietrich | Verfahren zur Abschätzung der Prognose und zur Prädiktion des Ansprechens auf eine Immuntherapie von Patienten mit malignen Erkrankungen |
| WO2017210341A1 (en) | 2016-05-31 | 2017-12-07 | The Regents Of The University Of California | Methods for evaluating, monitoring, and modulating aging process |
| EP3481403B1 (en) | 2016-07-06 | 2022-02-09 | Youhealth Biotech, Limited | Solid tumor methylation markers and uses thereof |
| US12351876B2 (en) | 2016-07-06 | 2025-07-08 | Helio Health, Inc. | Colon cancer methylation markers and uses thereof |
| US10093986B2 (en) | 2016-07-06 | 2018-10-09 | Youhealth Biotech, Limited | Leukemia methylation markers and uses thereof |
| EP3481941A4 (en) | 2016-07-06 | 2020-04-15 | Youhealth Biotech, Limited | METHYLIZATION MARKERS FOR BREAST AND OVARIAL CANCER AND THEIR USE |
| US12359257B2 (en) | 2016-07-06 | 2025-07-15 | Helio Health Inc. | Liver cancer methylation markers and uses thereof |
| CN106011278B (zh) * | 2016-07-18 | 2020-01-21 | 宁波大学医学院附属医院 | 人胃肠肿瘤中piezo2基因的检测试剂 |
| ES3035263T3 (en) | 2016-07-19 | 2025-09-01 | Exact Sciences Corp | Methylated control dna |
| ES2956257T3 (es) | 2016-09-02 | 2023-12-18 | Mayo Found Medical Education & Res | Detección de carcinoma hepatocelular |
| EP3336197B1 (en) | 2016-12-16 | 2022-04-06 | Eurofins Genomics Europe Sequencing GmbH | Epigenetic markers and related methods and means for the detection and management of ovarian cancer |
| JP7289264B2 (ja) | 2017-01-27 | 2023-06-09 | エグザクト サイエンシーズ コーポレーション | メチル化ｄｎａの分析による結腸腫瘍の検出 |
| CN110431241B (zh) | 2017-02-28 | 2024-04-19 | 梅约医学教育与研究基金会 | 检测前列腺癌 |
| BR112019018272A2 (pt) | 2017-03-02 | 2020-07-28 | Youhealth Oncotech, Limited | marcadores metilação para diagnosticar hepatocelular carcinoma e câncer |
| WO2018237327A1 (en) | 2017-06-22 | 2018-12-27 | Triact Therapeutics, Inc. | Methods of treating glioblastoma |
| WO2019012105A1 (en) | 2017-07-14 | 2019-01-17 | Université Libre de Bruxelles | METHOD OF PREDICTING SENSITIVITY TO IMMUNOTHERAPY |
| WO2019067991A1 (en) | 2017-09-29 | 2019-04-04 | Triact Therapeutics, Inc. | INIPARIB FORMULATIONS AND USES THEREOF |
| EP3692164B1 (en) | 2017-10-06 | 2025-10-15 | Helio Health Inc. | Methylation markers for diagnosing cancer |
| DE102017125780B3 (de) | 2017-11-05 | 2018-12-13 | Dimo Dietrich | Verfahren zur Bestimmung des Ansprechens einer malignen Erkrankung auf eine Immuntherapie |
| JP7277460B2 (ja) | 2017-11-30 | 2023-05-19 | マヨ ファウンデーション フォア メディカル エデュケーション アンド リサーチ | 乳癌の検出 |
| US11648551B2 (en) | 2017-12-12 | 2023-05-16 | Essenlix Corporation | Sample manipulation and assay with rapid temperature change |
| US10648025B2 (en) | 2017-12-13 | 2020-05-12 | Exact Sciences Development Company, Llc | Multiplex amplification detection assay II |
| EP3740589A4 (en) | 2018-01-17 | 2021-11-03 | The Regents of the University of California | BIOMARKERS BASED ON DNA METHYLATION AND PHENOTYPIC AGE FOR LIFE EXPECTANCY AND MORBIDITY |
| US11976332B2 (en) | 2018-02-14 | 2024-05-07 | Dermtech, Inc. | Gene classifiers and uses thereof in non-melanoma skin cancers |
| WO2020076983A1 (en) | 2018-10-10 | 2020-04-16 | The Regents Of The University Of California | Dna methylation based biomarkers for life expectancy and morbidity |
| CA3116424A1 (en) | 2018-10-17 | 2020-04-23 | The University Of Queensland | Epigenetic biomarker and uses therefor |
| US20220017966A1 (en) | 2018-11-16 | 2022-01-20 | Oslo Universitetssykehus Hf | Methods and compositions for characterizing bladder cancer |
| CA3126683A1 (en) | 2019-01-18 | 2020-07-23 | The Regents Of The University Of California | Dna methylation measurement for mammals based on conserved loci |
| WO2020154665A1 (en) | 2019-01-24 | 2020-07-30 | Mayo Foundation For Medical Education And Research | Detecting endometrial cancer |
| AU2020247911A1 (en) | 2019-03-26 | 2021-11-11 | Dermtech, Llc | Novel gene classifiers and uses thereof in skin cancers |
| CA3137726A1 (en) * | 2019-04-22 | 2020-10-29 | Behavioral Diagnostics, Llc | Compositions and methods for correcting for cellular admixture in epigenetic analyses |
| AU2020283954B2 (en) | 2019-05-28 | 2026-04-30 | Case Western Reserve University | Compositions and methods for preserving DNA methylation |
| US11396679B2 (en) | 2019-05-31 | 2022-07-26 | Universal Diagnostics, S.L. | Detection of colorectal cancer |
| US11001898B2 (en) | 2019-05-31 | 2021-05-11 | Universal Diagnostics, S.L. | Detection of colorectal cancer |
| US20220290245A1 (en) | 2019-09-11 | 2022-09-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Cancer detection and classification |
| US11702704B2 (en) | 2019-10-31 | 2023-07-18 | Mayo Foundation For Medical Education And Research | Detecting ovarian cancer |
| US11898199B2 (en) | 2019-11-11 | 2024-02-13 | Universal Diagnostics, S.A. | Detection of colorectal cancer and/or advanced adenomas |
| JP7757291B2 (ja) * | 2020-02-06 | 2025-10-21 | オンコホスト リミテッド | 治療法応答の機械学習予測 |
| CN119685477A (zh) | 2020-03-20 | 2025-03-25 | 上海鹍远健康科技有限公司 | 筛查结直肠瘤的方法和试剂盒 |
| US12467096B2 (en) | 2020-05-15 | 2025-11-11 | Universal Diagnostics, S.A. | Methods and systems for identifying methylation biomarkers |
| WO2021242872A1 (en) | 2020-05-27 | 2021-12-02 | Case Western Reserve University | Compositions and methods for preserving dna methylation |
| CA3183054A1 (en) * | 2020-06-29 | 2022-01-06 | Pentabase Aps | Detection of methylation status |
| WO2022002424A1 (en) | 2020-06-30 | 2022-01-06 | Universal Diagnostics, S.L. | Systems and methods for detection of multiple cancer types |
| JP2023539128A (ja) | 2020-08-19 | 2023-09-13 | マヨ ファウンデーション フォア メディカル エデュケーション アンド リサーチ | 非ホジキンリンパ腫の検出 |
| KR20230150814A (ko) | 2021-01-29 | 2023-10-31 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 다양한 유형의 암에 대한 존재 또는 부재의 검출 |
| CA3219484A1 (en) | 2021-05-25 | 2022-12-01 | Raymond F Anton | Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in individuals diagnosed with alcohol use disorder |
| IL311764A (en) | 2021-09-30 | 2024-05-01 | Tivenix Sa | A method for diagnosing and predicting progression of neurodegenerative diseases or disorders |
| CA3235235A1 (en) | 2021-10-19 | 2023-04-27 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Dna methylation signature for diagnosing hepatocellular carcinoma |
| EP4170661A1 (en) | 2021-10-19 | 2023-04-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methylation profile analysis using smoothing method |
| WO2023175019A1 (en) | 2022-03-15 | 2023-09-21 | Genknowme S.A. | Method determining the difference between the biological age and the chronological age of a subject |
| EP4299764A1 (en) | 2022-06-28 | 2024-01-03 | Universal Diagnostics, S.A. | Methods for detecting pancreatic cancer using dna methylation markers |
| US12606872B2 (en) | 2022-11-16 | 2026-04-21 | Universal Diagnostics, S.A. | Methods for stratification and early detection of advanced adenoma and/or colorectal cancer using DNA methylation markers |
| WO2024105132A1 (en) | 2022-11-16 | 2024-05-23 | Universal Diagnostics, S.A. | Methods for stratification and early detection of advanced adenoma and/or colorectal cancer using dna methylation markers |
| WO2024256726A1 (en) | 2023-06-15 | 2024-12-19 | Genknowme S.A. | Computer implemented method determining a value of allostatic load of a human being |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| ATE219776T1 (de) * | 1989-03-21 | 2002-07-15 | Us Secretary United States Dep | Matrizenmetalloproteinase-inhibitor-peptide |
| US5324634A (en) * | 1992-03-31 | 1994-06-28 | The Research Foundation Of State University Of New York | Diagnostic tests measuring gelatinase/inhibitor complexes for detection of aggressive and metastatic cancer |
| IL108978A (en) * | 1994-03-15 | 1998-02-22 | Yissum Res Dev Co | Assay for monitoring the progress of cml |
| US5856094A (en) * | 1995-05-12 | 1999-01-05 | The Johns Hopkins University School Of Medicine | Method of detection of neoplastic cells |
| US5871917A (en) * | 1996-05-31 | 1999-02-16 | North Shore University Hospital Research Corp. | Identification of differentially methylated and mutated nucleic acids |
-
1997
- 1997-04-11 US US08/835,728 patent/US6017704A/en not_active Expired - Lifetime
- 1997-06-03 DK DK97927933T patent/DK0954608T3/da active
- 1997-06-03 JP JP50077998A patent/JP3612080B2/ja not_active Expired - Lifetime
- 1997-06-03 EP EP97927933A patent/EP0954608B1/en not_active Expired - Lifetime
- 1997-06-03 IL IL12734297A patent/IL127342A/en not_active IP Right Cessation
- 1997-06-03 PT PT97927933T patent/PT954608E/pt unknown
- 1997-06-03 DE DE69735894T patent/DE69735894T2/de not_active Expired - Lifetime
- 1997-06-03 CA CA002257104A patent/CA2257104C/en not_active Expired - Lifetime
- 1997-06-03 EP EP06009975A patent/EP1690948A3/en not_active Withdrawn
- 1997-06-03 ES ES97927933T patent/ES2264165T3/es not_active Expired - Lifetime
- 1997-06-03 AT AT97927933T patent/ATE326549T1/de active
- 1997-06-03 WO PCT/US1997/009533 patent/WO1997046705A1/en not_active Ceased
-
2000
- 2000-01-25 US US09/490,558 patent/US6265171B1/en not_active Expired - Lifetime
-
2004
- 2004-05-24 JP JP2004153956A patent/JP3725535B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2257104A1 (en) | 1997-12-11 |
| ES2264165T3 (es) | 2006-12-16 |
| WO1997046705A1 (en) | 1997-12-11 |
| CA2257104C (en) | 2008-01-29 |
| DE69735894T2 (de) | 2007-04-19 |
| JP3612080B2 (ja) | 2005-01-19 |
| PT954608E (pt) | 2006-08-31 |
| EP1690948A3 (en) | 2006-11-22 |
| EP0954608A4 (en) | 2003-09-10 |
| EP0954608A1 (en) | 1999-11-10 |
| DK0954608T3 (da) | 2006-08-21 |
| DE69735894D1 (de) | 2006-06-22 |
| IL127342A0 (en) | 1999-10-28 |
| ATE326549T1 (de) | 2006-06-15 |
| JP2004290200A (ja) | 2004-10-21 |
| EP0954608B1 (en) | 2006-05-17 |
| US6017704A (en) | 2000-01-25 |
| JP2000511776A (ja) | 2000-09-12 |
| EP1690948A2 (en) | 2006-08-16 |
| US6265171B1 (en) | 2001-07-24 |
| JP3725535B2 (ja) | 2005-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6017704A (en) | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids | |
| US6200756B1 (en) | Methods for identifying methylation patterns in a CpG-containing nucleic acid | |
| EP0672181B1 (en) | Methods of detecting mammalian nucleic acids isolated from stool specimen and reagents therefor | |
| JP6673562B2 (ja) | 結腸直腸がんのエピジェネティックマーカー及び該マーカーを使用する診断法 | |
| US7601521B2 (en) | Detection of nucleic acid mutation associated with cancer by analysis of saliva | |
| US8785614B2 (en) | Aberrantly methylated genes in pancreatic cancer | |
| US20140315203A1 (en) | Dna methylation in colorectal and breast cancer diagnostic methods | |
| JP2005204652A (ja) | メチル化特異的プライマー伸長（ｍｓｐｅ）によるメチル化状況を検出するアッセイ | |
| JPWO2005021743A1 (ja) | 核酸増幅用プライマー及びこれを用いた大腸癌の検査方法 | |
| CA2612690C (en) | Methylation specific detection | |
| US7611841B2 (en) | Method for detecting methylation of promoter using restriction enzyme and DNA chip | |
| CN120989247A (zh) | 用于检测肺癌的组合物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| EXP | Patent expired |